Intec Pharma Ltd. (NTEC) Given a $15.00 Price Target at Oppenheimer Holdings, Inc.
Oppenheimer Holdings, Inc. set a $15.00 price target on Intec Pharma Ltd. (NASDAQ:NTEC) in a research report sent to investors on Friday. The firm currently has a buy rating on the biotechnology company’s stock.
NTEC has been the topic of several other reports. Zacks Investment Research raised shares of Intec Pharma from a sell rating to a hold rating in a report on Wednesday. CIBC reaffirmed an outperform rating and issued a $15.00 price objective (up from $10.00) on shares of Intec Pharma in a report on Thursday, September 21st. Finally, Roth Capital set a $10.00 price objective on shares of Intec Pharma and gave the company a buy rating in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $12.25.
Shares of Intec Pharma (NASDAQ NTEC) traded down 1.18% during midday trading on Friday, reaching $8.40. 42,442 shares of the company traded hands. The company has a 50 day moving average price of $8.61 and a 200 day moving average price of $8.61. Intec Pharma has a 1-year low of $4.20 and a 1-year high of $9.80. The company’s market capitalization is $115.40 million.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/10/14/intec-pharma-ltd-ntec-given-a-15-00-price-target-at-oppenheimer-holdings-inc.html.
A hedge fund recently raised its stake in Intec Pharma stock. Migdal Insurance & Financial Holdings Ltd. grew its holdings in Intec Pharma Ltd. (NASDAQ:NTEC) by 5.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 522,200 shares of the biotechnology company’s stock after acquiring an additional 25,000 shares during the period. Migdal Insurance & Financial Holdings Ltd. owned about 3.80% of Intec Pharma worth $2,977,000 at the end of the most recent quarter. Institutional investors and hedge funds own 16.41% of the company’s stock.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.